コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 patient type (with vs without systemic lupus erythematosus).
2 nt cell arteritis to 2.82 for systemic lupus erythematosus).
3 toantibodies in patients with systemic lupus erythematosus.
4 ficacy in off-label trials of Systemic Lupus Erythematosus.
5 oding regions associated with systemic lupus erythematosus.
6 , including Crohn disease and systemic lupus erythematosus.
7 disease, type 1 diabetes, and systemic lupus erythematosus.
8 kinase 2 in a murine model of systemic lupus erythematosus.
9 severity in a mouse model of systemic lupus erythematosus.
10 may limit immune responses in systemic lupus erythematosus.
11 n autoimmune diseases such as systemic lupus erythematosus.
12 is, rheumatoid arthritis, and systemic lupus erythematosus.
13 isms that are associated with systemic lupus erythematosus.
14 ibody-driven diseases such as systemic lupus erythematosus.
15 its increased production in cutaneous lupus erythematosus.
16 viable therapeutic target in systemic lupus erythematosus.
17 nflammatory bowel disease and systemic lupus erythematosus.
18 of BAFF-targeted therapies in systemic lupus erythematosus.
19 n AA, autoimmune uveitis, and systemic lupus erythematosus.
20 ividuals and in patients with systemic lupus erythematosus.
21 ic mouse model of spontaneous systemic lupus erythematosus.
22 s/PCs in patients with active systemic lupus erythematosus.
23 tracellular innate sensors in systemic lupus erythematosus.
24 disease in a murine model of systemic lupus erythematosus.
25 f autoimmune diseases such as systemic lupus erythematosus.
26 +) T cells from patients with systemic lupus erythematosus.
27 and are also associated with systemic lupus erythematosus.
28 locytes from individuals with systemic lupus erythematosus.
29 icated in the pathogenesis of systemic lupus erythematosus.
30 utoimmune diseases resembling systemic lupus erythematosus.
31 what is clinically defined as systemic lupus erythematosus.
32 ch as Alzheimer's disease and Systemic Lupus Erythematosus.
33 sculitis or inflammation, and systemic lupus erythematosus.
34 ffective for the treatment of systemic lupus erythematosus.
35 , spinocerebellar ataxia, and systemic lupus erythematosus.
36 IL-17A(high) subpopulation of systemic lupus erythematosus.
37 rthritis (98.1%), followed by systemic lupus erythematosus (0.79%), psoriasis (0.79%), and scleroderm
38 , psoriasis (18 [20.9%]), and systemic lupus erythematosus (12 [14.0%]) were the most common autoimmu
40 ammatory bowel disease, 2 had systemic lupus erythematosus, 2 had multiple sclerosis, 2 had autoimmun
41 gene that is associated with systemic lupus erythematosus(4,5)-interacts with the endolysosomal tran
42 es that are characteristic of systemic lupus erythematosus, a chronic autoimmune disease with multipl
43 in T cells from patients with systemic lupus erythematosus, a disease characterized by the overexpres
45 rthritis, sicca syndrome, and systemic lupus erythematosus (adjusted OR 1.49 [1.34-1.67], 3.47 [1.12-
48 h autoimmune diseases such as systemic lupus erythematosus, Aicardi-Goutieres syndrome (AGS) and fami
49 ed B cells from patients with systemic lupus erythematosus, an autoimmune disorder with a strong fema
50 chloroquine used for treating systemic lupus erythematosus and a Syk inhibitor blocked NA-TLR localiz
51 affect the kidneys, including systemic lupus erythematosus and anti-neutrophil cytoplasmic antibody-a
52 woman with recently diagnosed systemic lupus erythematosus and class IV lupus nephritis confirmed wit
53 An increase in clonality in systemic lupus erythematosus and Crohn's disease that was dominated by
55 lammatory diseases, including systemic lupus erythematosus and inflammatory bowel disease, and our pr
58 t new therapeutic targets for systemic lupus erythematosus and other diseases involving basophils and
59 d on studies in patients with systemic lupus erythematosus and other rheumatic conditions, there may
61 ory pathways in two systemic (systemic lupus erythematosus and rheumatoid arthritis) and two organ-sp
64 SA/Ro autoantibodies, such as systemic lupus erythematosus and Sjogren syndrome, are linked with an u
66 a role in the development of systemic lupus erythematosus and thus represent new therapeutic targets
67 in expression in B cells from systemic lupus erythematosus and type 1 diabetes patients, consequent t
68 mpared with Hodgkin lymphoma, systemic lupus erythematosus, and reactive lymph nodes, suggesting that
70 mia (AA), autoimmune uveitis, systemic lupus erythematosus, and sickle cell disease, respectively, as
71 g and common manifestation in systemic lupus erythematosus, and the etiology of this predisposition f
72 atory skin diseases including systemic lupus erythematosus, angioedema, pemphigus, bullous pemphigoid
73 ompared the BCR repertoire in systemic lupus erythematosus, anti-neutrophil cytoplasmic antibody (ANC
74 ogy observed in patients with systemic lupus erythematosus, autoreactive Abs secreted by autoreactive
75 icated in the pathogenesis of systemic lupus erythematosus because they secrete autoantibodies, but t
76 lls play an important role in systemic lupus erythematosus by acting not only as precursors of autoan
78 -Goutieres syndrome (AGS) and systemic lupus erythematosus, can arise when TREX1 function is compromi
81 values from all patients with systemic lupus erythematosus correlated positively with systemic lupus
85 us correlated positively with systemic lupus erythematosus disease activity index score (P = 0.033, P
86 ity was determined using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (
87 ng effects in mouse models of systemic lupus erythematosus-disease is exacerbated in TLR9-deficient m
90 s obtained from patients with systemic lupus erythematosus exhibited increased CD45 activity and BCR-
91 autoreactive B cells in SLE (systemic lupus erythematosus) focus on extrinsic stimuli and factors th
93 seases like Crohn disease and systemic lupus erythematosus, highlighting the value of examining cell-
94 was frequent in patients with systemic lupus erythematosus, in which it correlated to relative B cell
95 uman rheumatoid arthritis and systemic lupus erythematosus, indicating that increased autophagy as a
96 eumatoid arthritis, diabetes, systemic lupus erythematosus, inflammatory bowel disease, psoriasis, Sj
100 020) suggest that the IFN signature in lupus erythematosus (LE) alters expression of epithelial barri
102 We show here that active cutaneous lupus erythematosus lesions are highly colonized (~50%) by S.
103 tion of discoid and subacute cutaneous lupus erythematosus lesions showed significant epidermal up-re
106 /autoimmune disorders such as systemic lupus erythematosus; lymphoproliferative disorders such as chr
107 atoid arthritis (n = 25,324), systemic lupus erythematosus (n = 3,951), and/or vasculitis (n = 5,199)
108 re the primary treatment for cutaneous lupus erythematosus, not all patients are equally responsive.
111 care for patients with severe systemic lupus erythematosus or catastrophic antiphospholipid syndrome.
112 n autoimmune diseases such as systemic lupus erythematosus or psoriasis, but pDCs are also involved i
116 mmatory DC3s were expanded in systemic lupus erythematosus patients and correlated with disease activ
117 Siglec-1 expression in active systemic lupus erythematosus patients and, additionally, revealed inter
118 at emerge from the B cells of systemic lupus erythematosus patients can be restored by GA stimulation
123 an healthy controls and human systemic lupus erythematosus patients, metformin inhibits the transcrip
124 enia gravis patients, and six systemic lupus erythematosus patients, obtained by next-generation sequ
125 onuclear cells isolated from cutaneous lupus erythematosus patients, whereas QC and HCQ inhibited IFN
130 autoimmunity and established systemic lupus erythematosus, plasmacytoid dendritic cells are not effe
131 is, rheumatoid arthritis, and systemic lupus erythematosus predispose to atherosclerotic cardiovascul
133 ith type I diabetes mellitus, systemic lupus erythematosus, RA, and celiac disease, these results sug
134 n SJS/TEN and pre-existing depression, lupus erythematosus, recent pneumonia, chronic kidney disease,
135 /- 0.07, P = 7.78 x 10-3) and systemic lupus erythematosus (rg = 0.13 +/- 0.05, P = 3.76 x 10-3).
136 utoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis and systemic scleros
138 and future impact of AMDs on systemic lupus erythematosus, rheumatoid arthritis, and devastating mon
139 connective tissue disorders: systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis,
141 Basophils from patients with systemic lupus erythematosus show an activated phenotype, correlating t
142 h as rheumatoid arthritis and systemic lupus erythematosus, show a polygenic inheritance pattern.
143 er; systemic diseases such as systemic lupus erythematosus, Sjogren syndrome or Behcet disease and gr
144 ytokine profiles in lesional cutaneous lupus erythematosus skin could affect antimalarial responsiven
145 1D) (n = 200, HD n = 200), 3) systemic lupus erythematosus (SLE) (n = 200, HD n = 67; neuro-SLE n = 4
146 ron (IFN) drives pathology in systemic lupus erythematosus (SLE) and can be tracked via IFN-inducible
147 deficiency is associated with systemic lupus erythematosus (SLE) and increased susceptibility to seve
149 e rheumatic diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), is in
151 ance, the autoimmune diseases systemic lupus erythematosus (SLE) and Sjogren's syndrome affect nine t
152 (RA), osteoarthritis (OA), or systemic lupus erythematosus (SLE) and to identify metabolites associat
154 upus models and patients with systemic lupus erythematosus (SLE) arise as a consequence of defective
155 -23 receptor in patients with systemic lupus erythematosus (SLE) as compared with healthy controls.
156 Tfh cells from patients with systemic lupus erythematosus (SLE) but not primary antiphospholipid syn
157 the major IFNalpha source in systemic lupus erythematosus (SLE) but their phenotype and function in
160 ne expression data to predict systemic lupus erythematosus (SLE) disease activity is a significant ch
162 T cells from patients with systemic lupus erythematosus (SLE) display a number of abnormalities, i
167 nical trials in patients with systemic lupus erythematosus (SLE) has caused a profound sense of disap
172 heumatoid arthritis (RA), and systemic lupus erythematosus (SLE) increase susceptibility to destructi
204 sed studies have been done on systemic lupus erythematosus (SLE) mortality trends in the United State
208 ite advances in understanding systemic lupus erythematosus (SLE) pathogenesis, most clinical trials o
210 otal serum antibody Fabs in a systemic lupus erythematosus (SLE) patient sample and compared it to he
211 was replicated in a cohort of systemic lupus erythematosus (SLE) patients (N = 47) and controls (N =
213 ted lymphocytes isolated from systemic lupus erythematosus (SLE) patients compared to healthy control
214 ndscape of naive B cells from Systemic Lupus Erythematosus (SLE) patients undergoing disease flares.
217 n found to be associated with systemic lupus erythematosus (SLE) susceptibility by a recent genome-wi
218 f 39 variants associated with Systemic Lupus Erythematosus (SLE) through the integration of GWAS and
219 is a common manifestation of systemic lupus erythematosus (SLE) yet understanding of the underlying
221 isproportionately affected by systemic lupus erythematosus (SLE), a chronic, potentially debilitating
222 n autoimmune diseases such as systemic lupus erythematosus (SLE), a condition characterized by aberra
223 are associated with a risk of systemic lupus erythematosus (SLE), and mice lacking Irf5 are protected
224 VID), Evans syndrome (ES), or systemic lupus erythematosus (SLE), and most achieved a CR (N = 8), alt
225 autoimmune diseases, such as systemic lupus erythematosus (SLE), but the natural history of autoreac
226 ssociated with development of systemic lupus erythematosus (SLE), but the underlying mechanisms are i
227 n autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying mechanisms remai
229 of autoimmunity, most notably systemic lupus erythematosus (SLE), diabetes mellitus, and dermatomyosi
230 smoking, hyperopia, diabetes, systemic lupus erythematosus (SLE), greater deprivation (Townsend index
231 Here we found that in human systemic lupus erythematosus (SLE), IgE antibodies specific for double-
232 ribute to the pathogenesis of systemic lupus erythematosus (SLE), including autoreactive B cell activ
233 utoimmune diseases, including systemic lupus erythematosus (SLE), is an increased prevalence in women
237 utoimmune diseases, including systemic lupus erythematosus (SLE), Sjogren's syndrome, inflammatory bo
239 usceptibility and severity of systemic lupus erythematosus (SLE), using renal disease as a proxy for
240 R7)-dependent mouse models of systemic lupus erythematosus (SLE), we dissect dietary effects on the g
241 o autoimmune diseases such as systemic lupus erythematosus (SLE), where nucleic acid-containing immun
242 idal changes in patients with systemic lupus erythematosus (SLE), with or without glomerulonephritis;
243 une diseases, with a focus on systemic lupus erythematosus (SLE), with the relevant translational opp
244 e prevalent and pathogenic in systemic lupus erythematosus (SLE), yet mechanisms of their development
245 inflammation is recurrent in systemic lupus erythematosus (SLE), yet mechanisms that drive cutaneous
247 ysM(Cre)Bim(fl/fl)) develop a systemic lupus erythematosus (SLE)-like disease that mirrors aged Bim(-
248 T-bet promote autoimmunity in Systemic Lupus Erythematosus (SLE)-prone mouse models, the role for IFN
280 associated with the risk for systemic lupus erythematosus (SLE); however, it is unclear how Ox40L co
281 inflammation associated with systemic lupus erythematosus (SLE); however, it remains unclear whether
282 plasma from 35 patients with systemic lupus erythematosus (SLE; 15 with NPSLE) showed no antibodies
283 s with systemic sclerosis and systemic lupus erythematosus, suggesting a way to characterize CD4(+) T
285 such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, vasculitis or idiopat
286 is a common manifestation of systemic lupus erythematosus that can lead to irreversible renal impair
287 athy, Sjogren's syndrome, and systemic lupus erythematosus that have been controlled with immunosuppr
288 asis to alopecia areata to vitiligo to lupus erythematosus to atopic dermatitis and food allergy.
290 Using an inducible model of systemic lupus erythematosus, we found that passive transfer of antinuc
291 with rheumatoid arthritis and systemic lupus erythematosus were demethylated compared to healthy cont
292 l of autoimmunity, similar to systemic lupus erythematosus, where both cell types are critical for di
293 in the brain of patients with systemic lupus erythematosus with and without a history of central nerv
294 ncy causes familial monogenic systemic lupus erythematosus with childhood onset and anti-dsDNA reacti
295 callosum of 13 patients with systemic lupus erythematosus with past NPSLE, 16 patients with systemic
298 re made between patients with systemic lupus erythematosus with/without past NPSLE and healthy contro
299 most severe manifestations of systemic lupus erythematosus, with considerable morbidity and mortality
300 past NPSLE, 16 patients with systemic lupus erythematosus without past NPSLE, and 19 healthy control